- Home
- TWIN vs INBX Comparison
TWIN vs INBX Comparison
Compare TWIN & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TWIN | INBX |
|---|---|---|
| Founded | 1918 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 224.5M | 430.2M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | TWIN | INBX |
|---|---|---|
| Price | $15.74 | $81.50 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 2 |
| Target Price | ★ $12.00 | N/A |
| AVG Volume (30 Days) | 24.8K | ★ 236.0K |
| Earning Date | 02-04-2026 | 11-14-2025 |
| Dividend Yield | ★ 1.05% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $347,837,000.00 | $1,400,000.00 |
| Revenue This Year | $10.79 | $563.00 |
| Revenue Next Year | $8.43 | $230.77 |
| P/E Ratio | $826.62 | ★ N/A |
| Revenue Growth | ★ 14.24 | N/A |
| 52 Week Low | $6.16 | $10.81 |
| 52 Week High | $17.08 | $94.47 |
Technical Indicators
Market Signals| Indicator | TWIN | INBX |
|---|---|---|
| Relative Strength Index (RSI) | 53.52 | 52.21 |
| Support Level | $15.28 | $74.80 |
| Resistance Level | $16.09 | $94.47 |
| Average True Range (ATR) | 0.58 | 6.15 |
| MACD | 0.00 | -2.00 |
| Stochastic Oscillator | 69.06 | 30.07 |
Price Performance
Historical ComparisonAbout TWIN Twin Disc Incorporated
Twin Disc Inc is a United States-based firm engaged in the manufacture and sale of marine and heavy-duty off-highway power transmission equipment. The company operates its business through two reportable segments: Manufacturing and Distribution. Its product portfolio includes marine transmissions, surface drives, propellers, and boat management systems as well as power-shift transmissions, hydraulic torque converters, power take-offs, industrial clutches, and control systems.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.